www.fdanews.com/articles/198715-astrazeneca-begins-human-trials-of-covid-19-monoclonal-antibody
AstraZeneca Begins Human Trials of COVID-19 Monoclonal Antibody
August 26, 2020
AstraZeneca dosed its first participants in a phase 1 trial of its investigational monoclonal antibody product AZD7442 for preventing and treating COVID-19.
The trial will evaluate the safety, tolerability and pharmacokinetics of the treatment in up to 48 healthy participants ages 18 to 55 years old in the United Kingdom.
AZD7442 is a combination of two monoclonal antibodies that were discovered by researchers at Vanderbilt University Medical Center and licensed to AstraZeneca in June.